Simon Stertzer Acquires 39,000 Shares of BioCardia (NASDAQ:BCDA) Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 39,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was purchased at an average price of $1.00 per share, for a total transaction of $39,000.00. Following the completion of the transaction, the director directly owned 166,338 shares in the company, valued at approximately $166,338. The trade was a 30.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

BioCardia Stock Performance

NASDAQ BCDA opened at $1.09 on Friday. The stock has a fifty day moving average of $1.01 and a 200-day moving average of $1.17. The stock has a market capitalization of $12.40 million, a P/E ratio of -1.20 and a beta of 0.51. BioCardia, Inc. has a 52 week low of $0.78 and a 52 week high of $2.45.

BioCardia (NASDAQ:BCDA) last released its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Equities research analysts forecast that BioCardia, Inc. will post -0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BCDA. Geode Capital Management LLC grew its stake in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the period. DRW Securities LLC bought a new stake in BioCardia in the fourth quarter valued at about $72,000. Finally, Cetera Investment Advisers acquired a new position in BioCardia in the second quarter valued at about $40,000. 20.57% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of BioCardia in a research report on Tuesday, June 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioCardia currently has an average rating of “Hold” and a consensus target price of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.